The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers

BACKGROUND: Although high‐grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER‐2/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER‐2 directed therapy in t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Haddad, Robert I., Jo, Vickie Y., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Chau, Nicole G.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Head and Neck Cancers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356716/
https://ncbi.nlm.nih.gov/pubmed/32310325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0841
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars